ConferenceHeidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 26.03.2025 / 09:23 CET/CESTThe issuer is solely responsible for the content of this ...

The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...

Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 ...

The "Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. In the progressive ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2024 annual results as of 31 December 2024. Financial ...

Eli Lilly and Company (LLY) has expanded its LillyDirect digital healthcare platform to offer connections to independent ...

They glowed like shiny pearls plucked from exotic climes, gleaming through the smoke and haze of crowded cities built on industrial dirt and grime.

Regular mergers and acquisitions and collaboration deals are other key features of large drugmakers What's Shaping the Future of the Large-Cap Pharma Industry? Innovation and Pipeline Success ...

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.

Detailed price information for Fennec Pharmaceuticals Inc (FRX-T) from The Globe and Mail including charting and trades.

Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...

Even without the pertinent details of how these industry-focused tariffs would be targeted, it's hardly encouraging when the main official behind them takes pains to single out the pharmaceutical ...